Generic Ketamine Tablets vs Brand-Name Products

The ketamine tablet market exists in an unusual regulatory space. There is no FDA-approved oral ketamine tablet for psychiatric or pain use — meaning virtually all ketamine tablets prescribed for these conditions are compounded generics. Understanding the landscape of generic vs. brand-name ketamine products helps patients navigate quality, cost, and access.

The Current Landscape

Generic Compounded Ketamine Tablets

The vast majority of ketamine tablets in clinical use today are produced by compounding pharmacies:

• 503A pharmacies: Traditional compounding pharmacies that prepare medications under individual patient prescriptions. Quality depends on the specific pharmacy's practices and state oversight — see our guide on finding the best compounding pharmacies.
• 503B outsourcing facilities: Larger compounding operations that produce batches of medications under more stringent FDA oversight. These facilities follow current good manufacturing practices (cGMP) closer to pharmaceutical manufacturers.

Compounded ketamine is the same active ingredient (racemic ketamine hydrochloride) used in FDA-approved injectable formulations. The difference is in the dosage form — the compounding pharmacy creates the tablet or troche rather than a regulated pharmaceutical manufacturer.

Brand-Name Products

Ketalar: The only FDA-approved ketamine product currently on the market is Ketalar, an injectable formulation approved for anesthesia. It is not an oral tablet.

Spravato: Esketamine (the S-enantiomer) nasal spray is FDA-approved for TRD, but it is not a tablet and uses only one enantiomer.

Pipeline products: Several pharmaceutical companies are developing proprietary oral ketamine formulations seeking FDA approval for psychiatric indications. Clexio Biosciences is the most prominent, with an extended-release ketamine tablet in Phase 2/3 trials.

Key Comparisons

Quality Control

Compounded generics: Quality varies. Well-run pharmacies with PCAB accreditation or 503B status provide consistent, reliable products. Poorly managed pharmacies may have inconsistent potency, contamination risk, or inadequate quality testing. The FDA has issued warnings about specific compounding pharmacies for quality violations.

Brand-name (when available): Manufactured under strict cGMP with rigorous quality control, batch testing, stability data, and regulatory oversight. Each unit contains a verified amount of active ingredient. This consistency is the core advantage of brand-name products.

Cost

Compounded generics: $8-$30 per dose. Affordable and accessible. Not typically covered by insurance.

Brand-name (projected): When proprietary oral ketamine products reach market, pricing is expected to be substantially higher — potentially $50-$200+ per dose, based on the precedent set by Spravato and other specialty psychiatric medications. Insurance coverage would likely be available, potentially offsetting the higher list price for insured patients.

Availability

Compounded generics: Widely available today through any compounding pharmacy that handles controlled substances. Can be prescribed by any licensed prescriber with DEA authority.

Brand-name: No oral brand-name product is currently available for psychiatric use. When one is approved, distribution may be restricted (similar to Spravato's REMS program) or available through standard pharmacy channels depending on the approval conditions.

Formulation Flexibility

Compounded generics: Can be prepared in any dose, formulation (tablet, troche, capsule, solution), and combination the prescriber requests. This flexibility allows precise dose customization.

Brand-name: Fixed doses and formulations. Less flexibility but more standardization. Extended-release formulations in development may offer pharmacokinetic advantages (smoother plasma levels, reduced side effects) not achievable with current compounded immediate-release tablets.

Choosing a Compounding Pharmacy

Since compounded generics are the current reality for most patients, selecting a reputable pharmacy is important:

• Look for PCAB (Pharmacy Compounding Accreditation Board) accreditation
• 503B outsourcing facilities offer higher regulatory standards than 503A pharmacies
• Ask about potency testing and quality assurance procedures
• Verify the pharmacy has experience compounding ketamine specifically
• Check for any FDA warning letters or state board actions
• Ask your prescriber for pharmacy recommendations based on their clinical experience

What the Future May Hold

The landscape is likely to change as pharmaceutical companies bring oral ketamine products to market:

• FDA-approved oral ketamine tablets would provide standardized quality and dosing
• Insurance coverage would become more widely available
• REMS programs may or may not be required
• Compounded generics would likely remain available but could face regulatory pressure
• Pricing dynamics will depend on competition and insurance negotiations

For now, compounded generic ketamine tablets remain the standard of care for oral ketamine therapy, and they provide effective treatment when sourced from reputable pharmacies.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• FDA: Compounding — FDA resource on compounding pharmacy regulations, 503A and 503B distinctions, and quality standards